Biofourmis Selected by Vanderbilt University Medical Center for CAR T-Cell Therapy Study

Biofourmis has announced that Vanderbilt University Medical Center has selected Biofourmis to support a clinical study measuring the safety and efficacy of monitoring patients in a home-like outpatient setting after receiving a leading oncology drug.

Patients with large B-cell lymphoma will receive the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (YESCARTA®) by Kite, a Gilead Company. Instead of remaining in the hospital after receiving the immunotherapy, which is the current standard of care, patients will be discharged to a home-like setting near the medical center. In addition to periodic physical exams, several vital signs will be continuously monitored through Biofourmis’ analytics platform, which will assist the clinical team in detecting side effects of therapy to intervene as appropriate.